iRadimed Corporation (IRMD)

From the record

iRadimed Corporation's filings since 2017 show 1 warning event: a notice about its exchange listing (8-K item 3.01, the latest 2024-06-07) (its current reports).

From the record

iRadimed Corporation's 10 filed years say what it did: revenue went from $32 million in fiscal 2016 to $84 million in fiscal 2025, up 11.1% a year; it rose in 7 of 9 years; the deepest fall was 29% from fiscal 2016 to fiscal 2017; net income was positive in 10 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, iRadimed Corporation's diluted share count grew about 0.6% a year, and dividends and buybacks returned about 65% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 129 sales (84 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-09-30 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, iRadimed Corporation earned about 24 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 59 cents per dollar of everything the company owns. Leverage: it owed about 13 cents per dollar of assets, and net share issuance: its share count grew 0.5% over the year (the filed statements).

From the record

iRadimed Corporation's standing among 109 graded names in its industry family: revenue of $84 million in fiscal 2025 ranks in the top 50% by size; a net margin of 26.8% ranks in the top 4%; revenue growth of 16.3% a year over the last 3 filed years ranks in the top 46% (its annual reports).

From the record

iRadimed Corporation's leadership, from its insiders' filings and its current reports: the chief executive on the record is Susi, Roger E. (CEO, President, Chairman, as filed), filing under that title since 2020-07-29, 6.3 years (top 39% of its family); the 7 officers and directors filing in the last fifteen months have been on the record a median of 4.4 years (bottom 33%); 1 officer or director change was reported on Form 8-K since 2023-11-13, against the 7 people in charge now (top 6%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

iRadimed Corporation's room to grow, from the newest filed statements (fiscal 2025): cash of $51 million against no long-term debt tagged leaves 47% of its assets as net cash, top 16% of its family; cash from operations less capital spending is 20.5% of revenue (top 7%); a gross margin of 76.7% (top 18%); research spending of 3.5% of revenue (bottom 15%) (its annual report).

From the record

iRadimed Corporation's growth drivers, from the filed years to fiscal 2025: revenue grew 16.3% a year over the last three filed years against 11.1% over all 10, speeding up (top 18% of its family); the newest year grew 14.4% (top 47%); research spending grew 9.3% a year (top 37%); capital spending grew 111.3% a year (top 2%) (its annual reports). iRadimed Corporation tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

iRadimed Corporation's newest year against its own record: revenue of $84 million in fiscal 2025 came in 2.4% below the $86 million its prior three years' pace pointed to (top 47% of its family); net income of $22 million against a prior three-year average of $16 million (top 41%); a net margin of 26.8% against 25.5% before (bottom 30%) (its annual reports).